Skip to content

Clinical trials

Phase 4 Carcinoma, Hepatocellular trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Hepatocellular Phase: Phase 4 Clear all

105 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20052
20065
20078
20081
20093
20106
20117
20123
20134
20147
201510
20166
20173
20184
20193
20203
20213
20222
20238
20245
20254
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status40
Completed36
Recruiting10
Not yet recruiting9
Withdrawn3
Terminated3
Enrolling by invitation2
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University18
Taipei Veterans General Hospital, Taiwan7
Ain Shams University3
Guerbet3
Fudan University2
Kaohsiung Medical University Chung-Ho Memorial Hospital2
Qidong Gaitianli Medicines Co., Ltd2
Seoul National University Hospital2
The Second Affiliated Hospital of Chongqing Medical University2
Alexandria University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Hepatocellular105
Liver Neoplasms16
Recurrence8
Hepatitis B6
Fibrosis5
Hepatitis C, Chronic4
Hypertension, Portal4
Liver Cirrhosis4
Pancreatic Neoplasms4
Stomach Neoplasms4

Trials

Showing 1 to 25 of 105. Each trial links to its page on Pharma Observatory.

5 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.